GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Sonnet BioTherapeutics
Sonnet, an early-stage oncology biotech, is a highly speculative bet on its scientific platform. Its price is driven not by financial performance, but by news from preclinical and early clinical trials.
Share prices of companies in the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing a platform for creating immunotherapeutic drugs with longer-acting and better tolerability. We've categorized it under "Immuno-Oncology," and the chart below shows how investors value companies improving existing cancer treatments.
Broad Market Index - GURU.Markets
Sonnet BioTherapeutics is developing a platform for creating immunotherapeutic drugs with longer-acting, better-tolerated properties. It is a component of the GURU.Markets index. The chart below shows the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SONN - Daily change in the company's share price Sonnet BioTherapeutics
Sonnet BioTherapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the preclinical and clinical trials of its oncology drugs.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Sonnet BioTherapeutics Holdings, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with SONN's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Sonnet BioTherapeutics is a biotech company focused on immunology and oncology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Sonnet BioTherapeutics
Sonnet BioTherapeutics' year-to-date performance is a story of developing a new generation of immunotherapeutic drugs. Its 12-month market cap is entirely dependent on preclinical and early clinical trial data. The success of its platform, which delivers cytokines directly to tumors, could fundamentally improve their effectiveness.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Sonnet, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique developments in oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sonnet BioTherapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its immunotherapy platform. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Sonnet BioTherapeutics
Sonnet BioTherapeutics is a clinical-stage immuno-oncology company. Its monthly performance is entirely dependent on progress in its research and development. News of preclinical and early clinical trial results are the primary drivers of its value.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immuno-oncology is one of the most saturated areas in biotechnology, with numerous companies seeking their own approach to cancer treatment. The dynamics of this sector, visible in the graph, reflect this intense competition and scientific risks. Sonnet BioTherapeutics is also participating in this race.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sonnet BioTherapeutics is a clinical-stage biotech developing cancer immunotherapy. Its stock operates in the world of science, not finance. Its performance is entirely dependent on news about research progress, trial data, and regulatory decisions, leading to sharp price movements that are completely uncorrelated with overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Sonnet BioTherapeutics
The short-term volatility of Sonnet BioTherapeutics, an early-stage oncology company, is extremely high. Any news about preclinical studies of its drug delivery platform or partnerships could trigger sharp speculative stock price movements.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. This chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Sonnet BioTherapeutics shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. This chart shows how the company's shares react to this general "noise."
Market capitalization of the company, segment and market as a whole
SONN - Market capitalization of the company Sonnet BioTherapeutics
Sonnet BioTherapeutics' market cap is the financial valuation of a biotech company with a platform for improving drug delivery to tumors. The chart reflects investor expectations for its scientific approach. Its speculative dynamics reflect how the market evaluates the company's preclinical data and potential for partnerships.
SONN - Share of the company's market capitalization Sonnet BioTherapeutics within the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics develops innovative biologics for the treatment of cancer and inflammatory diseases using its targeted drug delivery platform. Its market share reflects the potential of its scientific technology. The chart below shows the market weighting of its approach to smart drug development.
Market capitalization of the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics develops immunotherapeutic drugs using its targeted delivery platform. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the search for more effective and safer drugs. Sonnet is betting on its technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cancer immunotherapy, as seen in the chart, is exploring new ways to deliver drugs. Sonnet BioTherapeutics is developing a platform for delivering cytokines directly to tumor tissue. Its capitalization is a risky bet that its technology will improve the efficacy and reduce the toxicity of this class of drugs.
Book value capitalization of the company, segment and market as a whole
SONN - Book value capitalization of the company Sonnet BioTherapeutics
Sonnet BioTherapeutics is investing in improving drug delivery to tumors. Currently in the R&D stage, the company is using its financial assets to develop a platform that binds immunotherapeutic drugs to the protein albumin, ensuring their accumulation in tumors.
SONN - Share of the company's book capitalization Sonnet BioTherapeutics within the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics, a biopharmaceutical company, develops innovative drugs. Its share of the sector's assets consists of R&D laboratories. Its value lies in its unique platform, which delivers cytokines directly to tumors, rather than relying on manufacturing facilities.
Market segment balance sheet capitalization - Oncology immuno-therapy
Sonnet BioTherapeutics is an R&D-stage oncology company, making its model asset-light. The company's value lies in its scientific platform for developing bispecific drugs. Compared to the entire biotech sector, its low capital intensity is typical of innovative R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
Sonnet BioTherapeutics' assets are not drugs, but rather a patented technology that allows cytokines to be "attached" to antibodies for precise tumor delivery. The company's balance sheet reflects the value of this platform. The chart shows how much capital is invested in developing more effective and safe immunotherapies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Sonnet BioTherapeutics
Sonnet BioTherapeutics is an oncology company developing drugs with improved tumor delivery. Its market value is determined by the valuation of its scientific platform. Investors are betting on its technology, which promises to make immunotherapy more effective and safe.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing a new form of cancer immunotherapy. Its value is the potential of its scientific platform. This chart illustrates a classic biotech story: a market valuation based on hopes for a future breakthrough bears almost no relation to the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Sonnet BioTherapeutics is an oncology company developing immunotherapy. Its value is determined by the potential of this innovative technology. This chart illustrates the extent to which biotech market valuations are based on future scientific breakthroughs rather than current tangible assets, which contrasts sharply with the market average.
Debts of the company, segment and market as a whole
SONN - Company debts Sonnet BioTherapeutics
Sonnet BioTherapeutics develops innovative immuno-oncology drugs. Advancing candidates through the preclinical and early clinical stages requires significant capital. This chart shows how the company uses funding to support its research and development efforts toward new cancer treatments.
Market segment debts - Oncology immuno-therapy
Sonnet BioTherapeutics is a clinical-stage oncology company developing a novel approach to drug delivery. Funding at this stage is critical and risky. This chart shows whether the company is pursuing the standard biotech equity capital model to fund its innovative, yet unproven, developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Sonnet BioTherapeutics
Sonnet BioTherapeutics, another immuno-oncology company in development, shows its dependence on external funding. The story is similar to many biotech companies: borrowed money is burned through labs and clinical trials in the hopes of a breakthrough. High debt means the company has no margin for error.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Sonnet BioTherapeutics is developing a platform for creating immunotherapeutic drugs with improved tumor delivery. This chart compares the debt raised for this cutting-edge research to the overall market capitalization of the immuno-oncology sector. It reflects the financial implications of developing more effective and safer cancer drugs.
Debt to book value of all companies in the market
Sonnet BioTherapeutics develops innovative drug delivery methods for immunotherapy. Like many early-stage biotech companies, it relies entirely on external funding. The chart shows how the company manages its capital. The absence or presence of debt, compared to the market, reflects its R&D funding strategy and investor confidence.
P/E of the company, segment and market as a whole
P/E - Sonnet BioTherapeutics
This chart for Sonnet BioTherapeutics, a clinical-stage oncology company, is a valuation of its drug delivery technology. Since it has no revenue, the company's value is based on the potential of its platform. The stock's performance reflects investors' faith that its approach will lead to the development of more effective and safer drugs.
P/E of the market segment - Oncology immuno-therapy
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Sonnet. The entire sector is valued based on expectations for future drugs. For investors, this benchmark reflects the overall level of optimism. This provides a useful backdrop for assessing expectations for Sonnet's drug delivery technology.
P/E of the market as a whole
Sonnet BioTherapeutics develops immunotherapeutic drugs using its platform, which is designed to deliver drugs directly to tumors. This chart shows the market's risk appetite, providing insight into how investors view the potential of this technology platform to create more effective and safer cancer treatments compared to existing approaches.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Sonnet BioTherapeutics
Sonnet BioTherapeutics is a biotech company developing immunotherapeutic drugs using its tumor-targeting platform. This chart reflects analyst expectations for its preclinical and clinical programs, demonstrating confidence that its technology will improve the effectiveness of cancer treatment.
%20P%2FE%20Sonnet%20BioTherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Sonnet-BioTherapeutics&v=1772679421336 "Chart of the company's future (projected) P/E Sonnet BioTherapeutics")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics develops innovative biologics for cancer treatment, leveraging its platform to improve the efficacy and safety of immunotherapy. This chart compares its future profitability expectations with the biotech sector, demonstrating the level of investor confidence in its technology, which is designed to deliver cytokines directly to tumors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772679421420 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Sonnet BioTherapeutics is developing innovative immunotherapy for cancer treatment. This chart shows the company's overall risk appetite. Sonnet's success depends on the results of clinical trials of its platform. A positive market environment helps with funding, but cannot replace scientific data, which is the primary driver of valuation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772679421476 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Sonnet BioTherapeutics
Sonnet BioTherapeutics is a clinical-stage immuno-oncology company developing a platform for creating more effective and safe biologic therapeutics. This chart shows the financial trajectory of this biotech innovation. Current results reflect investments in preclinical and clinical research.
Profit of companies in the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing a platform for creating bifunctional proteins designed to deliver immunotherapeutic drugs directly to tumor tissue. This chart illustrates the financial climate in the immuno-oncology sector, reflecting the high interest in technologies that can improve the effectiveness of cancer treatments and reduce their toxicity.
Overall market profit
Sonnet BioTherapeutics is a clinical-stage immuno-oncology company. Its prospects depend entirely on the success of its scientific platform. The need for cancer treatments remains unchanged by the economic climate. However, as with other biotech companies, raising capital for research is easier in a growing and optimistic market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Sonnet BioTherapeutics
Sonnet BioTherapeutics is developing an innovative platform for delivering cytokines (immune-regulating proteins) directly to tumors for cancer treatment. This timeline is a long-term, speculative model, reflecting analysts' confidence in the scientific potential of this complex but promising approach.
%20profit%20of%20the%20company%20Sonnet%20BioTherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Sonnet-BioTherapeutics&v=1772679421872 "Graph of future (projected) profit of the company Sonnet BioTherapeutics")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics develops innovative biologics for cancer treatment using its platform for direct tumor cytokine delivery. This chart shows forecasts for the biotech sector. Sonnet's future revenue depends on the success of its technology in improving the efficacy and reducing toxicity of immunotherapy in upcoming clinical trials.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772679421981 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Sonnet BioTherapeutics is developing a platform for creating immunotherapeutic drugs. For a research-stage company, access to funding is key. This graph, which displays the projected total revenue, is an indicator of overall market sentiment and investor willingness to invest in high-risk biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772679422016 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Sonnet BioTherapeutics
Sonnet BioTherapeutics is developing a platform for creating long-acting cytokine drugs for cancer immunotherapy. This chart reflects a purely speculative valuation. It shows that the company's value is based not on sales, but on investors' faith in the scientific potential of its technology.
P/S market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing a platform for creating bi- and tri-functional proteins designed to treat cancer. Its technology enables the direct delivery of cytokines to tumors. This chart reflects the average biotech valuation, helping to understand how the market values the potential of Sonnet's innovative and targeted platform compared to its peers.
P/S of the market as a whole
Sonnet BioTherapeutics is developing a platform for creating immunotherapeutic drugs that are delivered directly to tumors. This is an innovative approach in oncology. This graph of average market revenue estimates clearly demonstrates that the company's valuation is based not on current sales, but on the potential of its scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Sonnet BioTherapeutics
Sonnet BioTherapeutics is developing a platform for creating immunotherapeutic drugs with enhanced properties for cancer treatment. This chart reflects investors' confidence in the potential of this technology. The valuation is based on expected future revenues, which depend on the successful progress of its candidates through clinical trials.
%20P%2FS%20Sonnet%20BioTherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Sonnet-BioTherapeutics&v=1772679422554 "The graph of the company's future (projected) P/S Sonnet BioTherapeutics")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing a platform for the development of cytokine drugs for cancer treatment. This chart compares the company's future revenue expectations with its sector. It reflects investor confidence in its scientific approach, which aims to improve the efficacy and safety of immunotherapy.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772679422626 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Sonnet BioTherapeutics is a clinical-stage immuno-oncology company developing a platform for creating more effective and safe cytokine therapies. This chart shows overall revenue expectations, as Sonnet addresses one of the key challenges in immunotherapy. Success with its platform could expand the use of this class of drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772679422684 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Sonnet BioTherapeutics
Sonnet BioTherapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapy drugs. Because the company has no commercial products, its revenue, if reflected in this chart, is likely minimal and comes from grants or collaborative agreements.
Sales of companies in the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing a platform for creating biologics that are delivered directly to tumor tissue, enhancing their therapeutic effect. This graph reflects advances in oncology, where targeted drug delivery, like Sonnet's, is a key area for improving treatment effectiveness.
Overall market sales
Sonnet BioTherapeutics is developing an innovative cancer immunotherapy platform. Its future depends on successful clinical trials and capital raising. The growth in total economic revenue, reflected in this chart, improves the investment climate, making it easier for companies like Sonnet to finance their expensive and long-term R&D projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Sonnet BioTherapeutics
Sonnet BioTherapeutics is developing a platform for creating immunotherapeutic drugs that are delivered directly to tumors, potentially increasing their efficacy and safety. This schedule reflects analysts' expectations for the success of this technology in preclinical and clinical trials.
%20sales%20of%20the%20company%20Sonnet%20BioTherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Sonnet-BioTherapeutics&v=1772679422950 "Schedule of future (projected) sales of the company Sonnet BioTherapeutics")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics develops immunotherapeutics using its platform that delivers biologic drugs to tumor tissue. This chart shows forecasts for the immuno-oncology sector. It helps assess how innovative drug delivery methods can improve the efficacy and safety of cancer treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772679423029 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Sonnet BioTherapeutics, an immuno-oncology company, sees this chart as a marker of biotech investment attractiveness. The positive economic forecasts reflected here are driving capital inflows into the industry, which is critical for funding the development of their innovative tumor drug delivery platform.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772679423059 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Sonnet BioTherapeutics
Sonnet BioTherapeutics is a preclinical biotechnology company developing cancer immunotherapy drugs. Its current focus is purely on research and development. This chart illustrates the financial side of this process, showing the amount of investment the company is dedicating to developing its platform rather than to generating current profits.
Market segment marginality - Oncology immuno-therapy
Sonnet BioTherapeutics develops immunotherapeutic drugs using its platform for targeted drug delivery to tumor tissue. For a biotech company, efficacy is the ability of the technology to reduce toxicity and improve efficacy, which can accelerate R&D. The chart shows Sonnet's operating model compared to its competitors.
Market marginality as a whole
Sonnet BioTherapeutics is developing a platform for creating biologics with improved therapeutic properties for cancer treatment. This graph shows average profitability, and Sonnet is working to improve existing treatments. Their financial success will depend on the effectiveness of their platform and partnerships.
Employees in the company, segment and market as a whole
Number of employees in the company Sonnet BioTherapeutics
Sonnet BioTherapeutics develops innovative immunotherapy. Its team, visible in this graph, consists primarily of scientists. The small staff is typical for a preclinical biotech company focused on proving the concept of its technology platform.
Share of the company's employees Sonnet BioTherapeutics within the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing an innovative platform for creating immunotherapeutic drugs with improved tumor delivery. This chart shows the percentage of all scientists working in this cutting-edge field that Sonnet attracts. This reflects its scientific potential and the uniqueness of its technological approach.
Number of employees in the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing a platform for creating immunotherapeutic drugs with improved properties. It employs a small but highly qualified team of scientists. This graph shows that the company is in its early stages. Stability or modest growth in staff reflects focused work on preclinical research.
Number of employees in the market as a whole
Sonnet BioTherapeutics develops targeted immunotherapeutics. Its market capitalization and ability to hire staff depend entirely on the success of its scientific platform. This chart shows the overall economic situation, but for Sonnet, preclinical and clinical trial data are crucial.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Sonnet BioTherapeutics (SONN)
Sonnet BioTherapeutics is a preclinical biotech company. Its market capitalization reflects investors' bet on the success of its R&D platform. This chart clearly demonstrates that market value is determined not by the number of employees, but by the potential of their discoveries.
%20of%20the%20company%20Sonnet%20BioTherapeutics%20(SONN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Sonnet-BioTherapeutics-SONN&v=1772679423603 "Chart of market capitalization per employee (in thousands of dollars) of the company Sonnet BioTherapeutics (SONN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics develops innovative immunotherapeutics using its proprietary platform. Like many biotech startups, its value is determined by the prospects of its scientific research. This chart shows how much investors believe in this technology per scientist working on its development.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772679423697 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Sonnet BioTherapeutics is developing an innovative platform for delivering cytokines to tumors, enhancing their anticancer activity. This is an early-stage biotech. The chart shows the speculative market assessment of the technology's potential, where the intellectual contribution of a small scientific team could lead to the creation of a new class of drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772679423713 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Sonnet BioTherapeutics (SONN)
Sonnet BioTherapeutics is a biopharmaceutical company developing a platform (F\<sub\>H\</sub\>AB) for delivering drugs (cytokines) to tumors. This is an R&D business. This chart reflects the R&D capital burn per scientist. This represents an investment in scientific development that could yield significant returns in the future.
%20Chart%20Sonnet%20BioTherapeutics%20(SONN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Sonnet-BioTherapeutics-SONN&v=1772679423730 "Company Profit Per Employee (in thousands of dollars) Chart Sonnet BioTherapeutics (SONN)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics (SONN) is a biopharmaceutical company developing a platform for delivering therapeutic proteins to tumors (immuno-oncology). Currently in the preclinical and early clinical stages, the company is focused on R&D. This chart shows how effectively the team of scientists is using capital to advance their unique platform.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772679423810 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Sonnet BioTherapeutics is a clinical-stage biotech company developing a drug delivery platform (for example, in oncology). This is pure R&D. This graph would show negative profit per employee, which is normal for this sector. The company is investing in scientists to develop a technology that does not yet generate revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772679423895 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Sonnet BioTherapeutics (SONN)
Sonnet BioTherapeutics is a biopharmaceutical company developing immunotherapeutic drugs. During clinical development, this graph is an indicator of future potential. Any revenue per employee will likely be the result of strategic alliances rather than commercial sales, but it will signal progress.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Sonnet-BioTherapeutics-SONN&v=1772679424017 "Sales chart per company employee Sonnet BioTherapeutics (SONN)")
Sales per employee in the market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing a platform (F\<sub\>H\</sub\>AB) for delivering immunotherapeutic drugs to tumors. It is an R&D biotech company. This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required in this industry to successfully commercialize an R&D platform.
Sales per employee for the market as a whole
Sonnet BioTherapeutics (SONN) is a clinical-stage biotechnology company developing albumin-based immunotherapy for cancer treatment. It is an R&D company staffed by scientists. This graph shows the current (zero) commercial return per employee pending clinical breakthroughs.
Short shares by company, segment and market as a whole
Shares shorted by company Sonnet BioTherapeutics (SONN)
Sonnet BioTherapeutics is an early-stage biopharmaceutical company developing a platform for targeted cytokine delivery for cancer treatment. This is a high-risk area. The chart shows the number of investors betting that this technology will not prove safe (cytokines are toxic) or effective in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Sonnet-BioTherapeutics-SONN&v=1772679424169 "Short Shares Chart for the Company Sonnet BioTherapeutics (SONN)")
Shares shorted by market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing immunotherapy using its platform for targeted drug delivery to tumors. This indicator measures overall skepticism in the pharmaceutical industry. When it is high, it indicates that investors generally lack confidence in the success of clinical trials or anticipate funding challenges across the industry.
Shares shorted by the overall market
Sonnet BioTherapeutics is developing a platform for drug delivery to tumors. This is a high-tech, but very early-stage research project. This chart illustrates the general pessimism. When the market is fearful, it is intolerant of burning money. Companies like SONN, which need years and millions of dollars to reach commercialization, are the first to be hit by the sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Sonnet BioTherapeutics (SONN)
Sonnet BioTherapeutics is developing immunotherapeutic drugs using its targeted drug delivery platform. It's an early-stage biotech. This indicator tracks momentum, showing when speculative interest is overheating the stock (above 70) or when a lack of news is pushing it into oversold territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Sonnet-BioTherapeutics-SONN&v=1772679424372 "RSI 14 indicator chart for the company's stock Sonnet BioTherapeutics (SONN)")
RSI 14 Market Segment - Oncology immuno-therapy
Sonnet (SONN) is a "biotech" that delivers to tumors. Their platform (F\<sub\>H\</sub\>AB) attaches drugs (cytokines) to albumin (a blood protein) so they circulate longer and penetrate the tumor better. The "Oncology immuno-therapy" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of the *entire* segment. It helps us understand: is SONN's growth due to their R\&D, or is *the entire* biotech "overheated"?
RSI 14 for the overall market
Sonnet BioTherapeutics (SONN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SONN (Sonnet BioTherapeutics)
Sonnet BioTherapeutics is developing a platform (FHAB) that delivers therapeutic proteins, such as interleukin, directly to tumors. This chart shows the analysts' average 12-month target. It reflects their collective bet on whether this technology will improve the effectiveness of immunotherapy and successfully complete clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SONN-Sonnet-BioTherapeutics&v=1772679424501 "A chart showing analyst consensus forecasts for the expected stock price. SONN (Sonnet BioTherapeutics)")
The difference between the consensus estimate and the actual stock price SONN (Sonnet BioTherapeutics)
Sonnet BioTherapeutics is a biotech company developing an F(ab')-based platform for delivering immunotherapeutic drugs to tumors. This chart shows how far the current stock price differs from the "fair" value predicted by analysts. For an R&D company, this gap reflects the experts' faith in scientific breakthroughs and the success of their clinical programs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SONN-Sonnet-BioTherapeutics&v=1772679424534 "A chart showing the difference between the consensus forecast and the actual stock price. SONN (Sonnet BioTherapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Sonnet BioTherapeutics is developing an immunotherapy delivery platform (F\<sub\>H\</sub\>AB) for cancer treatment. As a clinical-stage company, its valuation is highly dependent on the overall risk appetite of investors in biotech. This chart shows analysts' expectations for the entire immunotherapy sector. It reflects whether experts believe in new breakthroughs in oncology or anticipate a "biotech winter."
Analysts' consensus forecast for the overall market share price
Sonnet BioTherapeutics is a biotech company developing a cancer immunotherapy platform. This is a high-risk sector, where success depends on clinical trial results. This chart reflects the overall risk appetite in the market. For Sonnet, which has yet to generate revenue, the overall analyst optimism (the rising chart) is critical to raising the capital needed to fund expensive research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Sonnet BioTherapeutics
Sonnet BioTherapeutics is a clinical-stage biotech focused on immuno-oncology. Their unique platform (FHAB) is designed to smuggle therapeutic drugs (cytokines) directly into tumors. This chart is purely an R&D barometer. It does not reflect sales, but rather a speculative assessment of their scientific platform and progress toward clinical milestones.
AKIMA Market Segment Index - Oncology immuno-therapy
Sonnet BioTherapeutics (SONN) uses its FHAB platform to develop immuno-oncology drugs that are designed to last longer in the body and target tumors more precisely. This is a highly competitive sector. This chart shows the average value of the composite index for the entire segment. Comparing Sonnet to this barometer allows investors to assess the market's confidence in the superiority of their technology over the average.
The AKIM Index for the overall market
Sonnet BioTherapeutics is a biotech company developing immunotherapy based on its FHAB tumor-targeting platform. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative early-stage scientific story compares to overall economic trends.
